vs
Side-by-side financial comparison of CytomX Therapeutics, Inc. (CTMX) and SmartRent, Inc. (SMRT). Click either name above to swap in a different company.
SmartRent, Inc. is the larger business by last-quarter revenue ($36.5M vs $18.7M, roughly 2.0× CytomX Therapeutics, Inc.). CytomX Therapeutics, Inc. runs the higher net margin — -0.8% vs -8.9%, a 8.1% gap on every dollar of revenue. On growth, SmartRent, Inc. posted the faster year-over-year revenue change (3.1% vs -25.7%). SmartRent, Inc. produced more free cash flow last quarter ($7.7M vs $-15.8M). Over the past eight quarters, SmartRent, Inc.'s revenue compounded faster (-15.0% CAGR vs -15.9%).
CytomX Therapeutics is a clinical-stage biotechnology company specializing in innovative cancer immunotherapies. It leverages its proprietary Probody technology platform to develop targeted therapies that activate exclusively in tumor microenvironments, minimizing off-target toxicities, with a pipeline covering multiple solid tumor indications and partnerships with leading global pharmaceutical firms.
Budget Rent a Car System, Inc. is an American car rental company that was founded in 1958 in Los Angeles, California by Morris Mirkin. Budget is a subsidiary of the Avis Budget Group, with its operations headquartered in Parsippany, New Jersey.
CTMX vs SMRT — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $18.7M | $36.5M |
| Net Profit | $-154.0K | $-3.2M |
| Gross Margin | — | 38.6% |
| Operating Margin | -6.9% | -10.9% |
| Net Margin | -0.8% | -8.9% |
| Revenue YoY | -25.7% | 3.1% |
| Net Profit YoY | 97.6% | 71.6% |
| EPS (diluted) | — | $-0.02 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $36.5M | ||
| Q3 25 | — | $36.2M | ||
| Q2 25 | $18.7M | $38.3M | ||
| Q1 25 | $50.9M | $41.3M | ||
| Q4 24 | $38.1M | $35.4M | ||
| Q3 24 | $33.4M | $40.5M | ||
| Q2 24 | $25.1M | $48.5M | ||
| Q1 24 | $41.5M | $50.5M |
| Q4 25 | — | $-3.2M | ||
| Q3 25 | — | $-6.3M | ||
| Q2 25 | $-154.0K | $-10.9M | ||
| Q1 25 | $23.5M | $-40.2M | ||
| Q4 24 | $18.9M | $-11.4M | ||
| Q3 24 | $5.7M | $-9.9M | ||
| Q2 24 | $-6.5M | $-4.6M | ||
| Q1 24 | $13.8M | $-7.7M |
| Q4 25 | — | 38.6% | ||
| Q3 25 | — | 26.4% | ||
| Q2 25 | — | 33.1% | ||
| Q1 25 | — | 32.8% | ||
| Q4 24 | — | 28.7% | ||
| Q3 24 | — | 33.2% | ||
| Q2 24 | — | 35.7% | ||
| Q1 24 | — | 38.5% |
| Q4 25 | — | -10.9% | ||
| Q3 25 | — | -19.4% | ||
| Q2 25 | -6.9% | -30.5% | ||
| Q1 25 | 44.4% | -99.9% | ||
| Q4 24 | 46.4% | -36.6% | ||
| Q3 24 | 12.3% | -29.0% | ||
| Q2 24 | -33.7% | -14.3% | ||
| Q1 24 | 28.1% | -20.1% |
| Q4 25 | — | -8.9% | ||
| Q3 25 | — | -17.3% | ||
| Q2 25 | -0.8% | -28.3% | ||
| Q1 25 | 46.2% | -97.2% | ||
| Q4 24 | 49.6% | -32.3% | ||
| Q3 24 | 17.2% | -24.5% | ||
| Q2 24 | -26.0% | -9.5% | ||
| Q1 24 | 33.3% | -15.2% |
| Q4 25 | — | $-0.02 | ||
| Q3 25 | — | $-0.03 | ||
| Q2 25 | — | $-0.06 | ||
| Q1 25 | — | $-0.21 | ||
| Q4 24 | — | $-0.06 | ||
| Q3 24 | — | $-0.05 | ||
| Q2 24 | — | $-0.02 | ||
| Q1 24 | — | $-0.04 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $49.0M | $104.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $119.9M | $232.1M |
| Total Assets | $175.1M | $320.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $104.5M | ||
| Q3 25 | — | $100.0M | ||
| Q2 25 | $49.0M | $105.0M | ||
| Q1 25 | $47.6M | $125.6M | ||
| Q4 24 | $38.1M | $142.5M | ||
| Q3 24 | $40.6M | $163.4M | ||
| Q2 24 | $43.2M | $187.4M | ||
| Q1 24 | $36.2M | $204.7M |
| Q4 25 | — | $232.1M | ||
| Q3 25 | — | $234.4M | ||
| Q2 25 | $119.9M | $238.8M | ||
| Q1 25 | $25.0M | $250.7M | ||
| Q4 24 | $-456.0K | $289.4M | ||
| Q3 24 | $-23.5M | $305.1M | ||
| Q2 24 | $-31.2M | $329.4M | ||
| Q1 24 | $-31.7M | $333.1M |
| Q4 25 | — | $320.9M | ||
| Q3 25 | — | $335.8M | ||
| Q2 25 | $175.1M | $354.0M | ||
| Q1 25 | $98.5M | $366.1M | ||
| Q4 24 | $120.5M | $420.2M | ||
| Q3 24 | $139.0M | $448.6M | ||
| Q2 24 | $159.2M | $475.3M | ||
| Q1 24 | $184.7M | $485.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.8M | $7.7M |
| Free Cash FlowOCF − Capex | $-15.8M | $7.7M |
| FCF MarginFCF / Revenue | -84.6% | 21.0% |
| Capex IntensityCapex / Revenue | 0.1% | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-77.7M | $-25.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $7.7M | ||
| Q3 25 | — | $-2.1M | ||
| Q2 25 | $-15.8M | $-14.9M | ||
| Q1 25 | $-21.0M | $-12.2M | ||
| Q4 24 | $-19.9M | $-12.0M | ||
| Q3 24 | $-20.7M | $-3.7M | ||
| Q2 24 | $-19.5M | $-13.9M | ||
| Q1 24 | $-26.0M | $-3.3M |
| Q4 25 | — | $7.7M | ||
| Q3 25 | — | $-2.2M | ||
| Q2 25 | $-15.8M | $-16.2M | ||
| Q1 25 | $-21.2M | $-14.3M | ||
| Q4 24 | $-20.0M | $-13.3M | ||
| Q3 24 | $-20.7M | $-3.9M | ||
| Q2 24 | $-19.6M | $-14.1M | ||
| Q1 24 | $-26.2M | $-3.4M |
| Q4 25 | — | 21.0% | ||
| Q3 25 | — | -6.1% | ||
| Q2 25 | -84.6% | -42.3% | ||
| Q1 25 | -41.6% | -34.7% | ||
| Q4 24 | -52.5% | -37.5% | ||
| Q3 24 | -62.1% | -9.7% | ||
| Q2 24 | -78.2% | -29.1% | ||
| Q1 24 | -63.1% | -6.7% |
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | 0.2% | ||
| Q2 25 | 0.1% | 3.3% | ||
| Q1 25 | 0.2% | 5.3% | ||
| Q4 24 | 0.2% | 3.5% | ||
| Q3 24 | 0.1% | 0.6% | ||
| Q2 24 | 0.4% | 0.5% | ||
| Q1 24 | 0.3% | 0.1% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -0.89× | — | ||
| Q4 24 | -1.05× | — | ||
| Q3 24 | -3.61× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -1.89× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
SMRT
| Hosted Services | $18.1M | 50% |
| Hardware Service | $12.5M | 34% |
| Smart Operations Solutions | $2.6M | 7% |
| Access Control | $2.0M | 5% |
| Other Smart Communities Solutions | $1.3M | 3% |
